NVO
Novo Nordisk A S
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Novo Nordisk A S
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
No changes.
No changes.
No thesis.
Annual filing, covered
20-F parsed · Feb 4 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Feb 4 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
—
Expected move
No implied move.
Novo Nordisk A S
39.98
+0.84 · +2.15%
post 39.94 −0.10%
Closest co-movers of Novo Nordisk A S; it has no SEC industry code.
Closest co-movers of Novo Nordisk A S; it has no SEC industry code.
| Manager | Value | % base | |
|---|---|---|---|
| Susquehanna International | $1.2B | 6.26% | −17.31% |
| Dodge & COX | $977.8M | 4.98% | +5.50% |
| Citadel | $923.2M | 4.70% | −4.38% |
| Loomis Sayles & Co L P | $891.4M | 4.54% | +9.27% |
| Franklin Resources | $625.2M | 3.18% | −18.92% |
| Manager | Value | % base | |
|---|---|---|---|
| Susquehanna International | $1.2B | 6.26% | −17.31% |
| Dodge & COX | $977.8M | 4.98% | +5.50% |
| Citadel | $923.2M | 4.70% | −4.38% |
| Loomis Sayles & Co L P | $891.4M | 4.54% | +9.27% |
| Franklin Resources | $625.2M | 3.18% | −18.92% |
News
Linked news